




APIs Pipeline

Letermovir



Letermovir (CAS-RN 917389-32-3) is an antiviral agent approved in 2017 by US FDA to be used in prophylaxis of cytomegalovirus (CMV) infection and disease in adult CMV-seropositive recipients of an allogeneic hematopoietic stem cell transplant (HSCT). Designated an orphan drug by FDA for prevention of CMV viremia and disease in at-risk populations.

Main Therapeutic Application

ANTIVIRAL

CAS-RN

917389-32-3

Specification

In House

Documentation

Under Development

Lebsa

+34 93 377 00 51
lebsa@lebsa.com
www.lebsa.com

MADE IN EUROPE

HEADQUARTERS:
Ctra. de l'Hospitalet, 34
08940 Cornellà (Barcelona)
SPAIN

**Are you looking for
other molecules?**

For more information about our R&D
pipeline and CDMO services

CONTACT US